published meta-analysis   sensitivity analysis   studies

Emtricitabine/tenofovir plus colchicine plus rosuvastatin in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17] 0.62[0.33; 1.17]Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 202110%320NAnot evaluable deathsdetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17] 0.62[0.33; 1.17]Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 202110%320NAnot evaluable mechanical ventilationdetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95] 0.70[0.52; 0.95]Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 202110%281NAnot evaluable ICU admissiondetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10] 0.87[0.69; 1.10]Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 202110%226NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:58 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1142 - roots T: 290